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Deidre B. Pereira,1 Lisa M. Christian,2 Seema Patidar,1 Michelle M. Bishop,1,3
Stacy M. Dodd,1 Rebecca Athanason,1 John R. Wingard,3 Vijay S. Reddy4Religiosity and spirituality have been associated with better survival in large epidemiologic studies. This study
examined the relationship between spiritual absence and 1-year all-cause mortality in allogeneic hematopoi-
etic stem cell transplant (HSCT) recipients. Depression and problematic compliance were examined as pos-
sible mediators of a significant spiritual absence-mortality relationship. Eighty-five adults (mean5 46.85 years
old, SD5 11.90 years) undergoing evaluation for allogeneic HSCT had routine psychologie evaluation prior
to HSCTadmission. The Millon Behavioral Medicine Diagnostic was used to assess spiritual absence, depres-
sion, and problematic compliance, the psychosocial predictors of interest. Patient status at 1 year and survival
time in days were abstracted from medical records. Cox regression analysis was used to examine the rela-
tionship between the psychosocial factors of interest and mortality after adjusting for relevant biobehavioral
factors. Twenty-nine percent (n5 25) of participants died within 1 year of HSCT. After covarying for disease
type, individuals with the highest spiritual absence and problematic compliance scores were significantly
more likely to die 1-year post-HSCT (hazard ratio [HR] 5 2.49, P 5 .043 and HR 5 3.74, P 5 .029, respec-
tively), particularly secondary to infection, sepsis, or graft-versus-host disease (GVHD) (HR5 4.56, P5 .01
andHR5 5.61, P5.014), relative to thosewithout elevations on these scales. Depression was not associated
with 1-year mortality, and problematic compliance did not mediate the relationship between spiritual
absence and mortality. These preliminary results suggest that both spiritual absence and problematic
compliance may be associated with poorer survival following HSCT. Future research should examine these
relations in a larger sample using a more comprehensive assessment of spirituality.
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Since the establishment of the National Marrow
Donor Program in 1987, over 30,000 unrelated donor
hematopoietic stem cell transplants (HSCT) have been
facilitated. Over 70% of these recipients have been
adults with hematologic malignancies, such as acute
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6/j.bbmt.2010.03.003logic conditions, such as severe aplastic anemia. Over
the past 20 years, HSCT treatment mortality has
significantly declined in tandem with significant
improvements in 1- and 2-year survival rates. None-
theless, between 2003 and 2006, the 1-year mortality
rate following HSCT for the acute leukemias and
myelodysplastic syndrome (MDS) still approached ap-
proximately 50%, suggesting that hematologic malig-
nancies treated withHSCT cause substantial mortality
among adults [1].
Over the past 15 years, there has been considerable
interest in identifying psychosocial predictors of mor-
tality among HSCT recipients [2]. Although these
studies differ in disease inclusion criteria, follow-up
period length, and psychosocial assessment methodol-
ogy, several factors have emerged across these studies
as predictors of poorer survival following HSCT.
Anxious preoccupation [3], distraction coping [4],
problematic social support [5], depressive symptoms
[6-9], and poorer functional quality of life [3] have
been associated with poorer survival post-HSCT,
whereas higher levels of available social support [10]1171
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better survival post-HSCT.
Religiosity and spirituality are 2 common methods
by which people cope with stressful life events, such as
the diagnosis and treatment of a life-limiting illness
[11,12]. Approximately 84% of Americans report
affiliation with a religion, and 82% report religion as
at least somewhat or very important in their lives
[13]. In 2 recent large-scale studies of cancer survivors,
62% reported being ‘‘very’’ or ‘‘moderately’’ religious
[14], 69% reported having prayed for their own health
[15], and 65% reported being ‘‘very’’ or ‘‘moderately’’
spiritual [14]. Two smaller-scale studies with more
homogenous cancer patient populations (ie, malignant
melanoma only, breast cancer only) suggest that nearly
85% to 90% of patients report that they are spiritual
or that spirituality is important in their lives [16,17].
Despite the fact that religiosity and spirituality have
been described as the most commonly used
‘‘complementary therapies’’ by individuals with
cancer [14], no published research has examined the
relationship between spirituality and health outcomes
in HSCT recipients.
Several systematic reviews of the literature support
a relationship between greater religious involvement
and lower all-cause mortality [18,19]. In several large-
scale studies, less frequent religious attendance
[20,21] and participation [22] were associated with
greater odds/hazards ratios ofmortality, and these rela-
tionships were at least partially explained by poorer
health status [20], less social integration [20], engage-
ment in unhealthy behaviors [20,21], and greater
systemic inflammation [21,22] among individuals
low in religiosity. Less is known about whether
spirituality (a cognitive schema that organizes one’s
approach to coping with difficult life circumstances
[12]) per se is associated with lower all-causemortality.
Furthermore, few studies have examined the relation-
ship between either religiosity or spirituality and
cancermorality, specifically. The few published studies
in this area have not supported a robust relationship
between religiosity/spirituality and cancer mortality,
particularly after controlling for biobehavioral
confounding variables [19]. For instance, although
Van Ness and colleagues [23] found that women with
breast cancer who reported having no religious denom-
ination preference had a greater hazard ratio of breast
cancer mortality, other measures of religiosity were
unrelated to breast cancer mortality, and spirituality
was not assessed. Thus, the possibility exists that lack
of documented relationship between religiosity/spiri-
tuality and cancer mortality may be partially because
of the relative lack of methodologically strong studies
that incorporate measures of spirituality in addition
to religious participation [19].
The purpose of the present study was to examine
the relationship between spirituality and 1-yearsurvival among HSCT recipients. It was hypothesized
that individuals high in spiritual absence would have
greater hazards of mortality than individuals high in
spiritual faith. Gall andGrant [12] posit that a relation-
ship between spirituality and positive health outcome
may be mediated by positive affect and engagement
in healthy behaviors. Consistent with this theory,
high levels of depressedmood and poormedical adher-
ence were examined as mediators of a significant
spiritual absence-mortality relationship.PATIENTS AND METHODS
Data for the present study were collected as part of
a larger study [24-26] examining immune status,
immune functioning, and clinical outcomes among
HSCT recipients (N 5 209). The present sample
included 85 individuals who underwent routine pre-
HSCT diagnostic interviews in the Psychology Clinic
at the University of Florida, completed the Millon Be-
havioral Medicine Diagnostic (MBMD) [27] at that
visit, subsequently underwent HSCT between 2002
and 2006, and survived at least 30 days post-HSCT.
One hundred twenty-three individuals enrolled in
the larger study were not included in the present sam-
ple because they were not administered the MBMD.
(Prior to 2004, some Psychology Clinic providers
administered alternate psychosocial instruments to
HSCT candidates.) One individual with MBMD data
was excluded, as her post-HSCT survival was \30
days. All study procedures were approved by the
institutional review board at the University of Florida
Health Science Center in accordance with an assur-
ance filed with and approved by the Department of
Health and Human Services, and informed consent
was obtained from each participant.Study Measures
Spirituality and associated factors
The MBMD is a 165-item true/false self-report
instrument that assesses psychosocial factors that
may influence the course of treatment of medical ill-
ness. It has excellent reliability and validity [27]. The
MBMD contains 7 domains, including Response Pat-
terns, Negative Health Habits, Psychiatric Indica-
tions, Coping Styles, Stress Moderators, Treatment
Prognostics, and Management Guides. Spiritual
absence versus spiritual faith is a Stress Moderator
scale that assesses the degree to which patients lack
religious or spiritual personal resources to cope with
medical stressors. Individuals scoring high on spiritual
absence often endorse the following items ‘‘I am not
a very spiritual person’’ and ‘‘I have no deep religious
beliefs.’’ The spiritual absence scale correlates highly
(0.75-0.85) with the most widely used medically
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Inventory (SBI) [28]. As per the theory outlined by
Gall and Grant [12], spiritual absence may be associ-
ated with negative health outcomes via maladaptive
health behaviors and/or maintenance/exacerbation of
negative mood. Therefore, the present study also
examined the degree to which problematic compliance
versus optimal compliance (a Treatment Prognostic
scale) and depression (a Psychiatric Indication scale)
may have accounted for a possible relationship
between Spiritual Absence and HSCT survival. Non-
compliant individuals are likely to response False to
items such as ‘‘I make sure that I’m on time for all
my doctor’s appointments’’ and ‘‘I would change my
lifestyle on my doctor’s advice.’’ Individuals scoring
high on the depression scale often endorse the follow-
ing items: ‘‘I’ve lost interest in things that I used to find
pleasurable’’ and ‘‘I have been having serious thoughts
about suicide.’’ The MBMD Depression scale
correlates highly (0.72-0.87) with the widely used
Beck Depression Inventory (BDI) [29].
The MBMD yields a Prevalence Score (PS) for
each subscale. A PS of 75 to 84 suggests that the factor
is a moderate or present liability for the health and
well-being of the patient, whereas a PS of 85 to 115
suggests that the factor is a marked or prominent
liability for the health and well-being of the patient.
Thus, spiritual absence, problematic compliance, and
depression were coded as ‘‘no liability’’ (‘‘0’’), ‘‘moder-
ate liability’’ (‘‘1’’), or ‘‘marked liability’’ (‘‘2’’).Patient characteristics, health behaviors, and
health/treatment status
Patient characteristics, including age and race/eth-
nicity; health behaviors, including use of psychotropic
medications and/or corticosteroids (either ofwhich can
influence mood and behavior); and health/treatment
status variables, including cancer type, disease risk
group (ie, risk for treatment failure based upon disease
type and status, see Tables 1 and 2 for a description of
these risk groups) [26] and HSCT type (myeloablative
or nonmyeloablative) were collected via patient inter-
view and/or medical record review and abstraction.
Survival
Patient survival time and status were abstracted
from medical records in January 2010. Survival time
was calculated in number of days after HSCT until
death (event) or date of last documented visit to the
UF Health Science Center (censored). Patient
status (censored [‘‘0’’] or event [‘‘1’’]) at 1-year post-
HSCT was then calculated from these data. The
primary outcome variable was 1-year all-cause mortal-
ity; however, 1-year HSCT-related mortality was
examined as a secondary outcome variable. HSCT-
related mortality was defined as death due totransplant-associated infection, sepsis, or graft-versus-
host disease (GVHD).
Statistical Analyses
Descriptive statistics were first computed on all
study variables. Participants from the larger study
with complete psychological and MBMD data
(n 5 85) were compared to those without complete
psychological and/or MBMD data (n5 124) on major
demographic and health treatment/status variables
using one-way analysis of variance (ANOVA) and
chi-square analyses. Univariate Cox regression analysis
was used to assess the relationship between potential
biobehavioral control variables (eg, age, disease risk
group, and HSCT type) and 1-year survival. Variables
significantly associated with survival at P # .05 were
entered as covariates into subsequent multivariate
Cox regression analyses. Multivariate Cox regression
analyses were then used to determine the hazards ratio
(HR) for survival associated with spiritual absence,
problematic compliance, and depression liability
groups, respectively, after adjusting for biobehavioral
covariates. Survival functions were plotted to illustrate
the relationship between liability groups and survival.RESULTS
The85patients in the present studywere compared
to the 124 patients without a psychosocial evaluation
and/or MBMD data from the larger study on major
demographic and health status/treatment variables to
assess for any systematic differences between the 2
groups. The 85 patients in the present study did not
differ from the 124 patients form the larger study on
age, sex,HSCT type, disease type, participant relation-
ship to donor, or graft source at P # .05. A greater
proportion of participants from the larger study were
classified as having high disease risk compared to those
in the present study, c2 (1, N 5 209) 5 4.33, P 5 .04
(Table 1).
Table 1 presents the participants’ characteristics.
Briefly, participants were 46 adult males (54%) and
39 adult females (46%) with a mean age of 46.85 years
(SD 5 11.90 years) who were mostly White, non-
Hispanic (86%, n 5 73), and married (76%, n 5 65).
The majority of patients were diagnosed with acute
leukemia or MDS (63%, n 5 54) whose disease was
classified as having a high risk of treatment failure
(73%, n 5 62). Sixty-nine percent (n 5 59) of partici-
pants underwent peripheral blood stem cell transplant.
Twenty-nine percent (n 5 25) of participants died
within 1 year post-HSCT. The mean number of days
survived for patients who died within 1 year was 174
(SD5 124). For the 71% (n5 60) of patients who lived
longer than 1-year post-HSCT, the mean number of
days survived was 1043 (SD 5 406). Percentages of
Table 1. Participant Characteristics
Variable No. % Mean SD
Age* 46.85 11.90
Sex*
Male 46 54
Female 39 46
Married
Single/never married, divorced,
widowed
19 22
Married 65 76
Not reported 1 2
Race/ethnicity
White, non-Hispanic 73 86
Black/African-American 4 5
Hispanic 6 7
Asian 1 1
Not reported 1 1
Tobacco use at pretransplant
Lifetime nonuser 42 49
Current user (within Last 90 days) 7 8
Past user (>90 days abstinence) 36 42
Alcohol use at pretransplant
Lifetime nonuser 37 44
Current user (within last 90 days) 24 28
Past user (>90 days abstinence) 24 28
Marijuana use at pretransplant
Lifetime nonuser 76 89
Current user (within last 90 days) 0 0
Past user (>90 days abstinence) 9 11
Psychotropic medication/steroid use
at pretransplant
No 54 64
Yes 28 33
Not reported 3 3
Caregiver identified at pretransplant
No 2 2
Yes 83 98
HSCT Type*
Nonmyeloablative 28 33
Myeloablative 57 67
Participant relation to donor*
Related 48 56
Unrelated 37 44
Graft Source*
Bone marrow 23 27
Peripheral blood stem cell 59 69
Umbilical cord 3 4
Disease risk*,†,‡
Low 23 27
High 62 73
Acute leukemia or myelodysplastic
syndrome*
No 31 37
Yes 54 63
Developed aGVHD§
No 63 74
Yes 21 25
Developed cGVHD by
1 year§,¶
No 39 46
Yes 18 21
Died within 1 year
No (censored) 60 71
Yes (expired) 25 29
Days survived
Participants expired at 1 year 173.56 124.02
Participants censored at 1 year 1043.15 406.23
Total sample 787.39 528.36
Primary cause of death at 1 year
Disease progression 12 46
GVHD 4 25
Infection/sepsis 8 35
New/secondary malignancy 1 4
(Continued )
Table 1. (Continued )
Variable No. % Mean SD
Spiritual absence liability group
No liability 70 82
Moderate liability 3 4
Marked liability 12 14
Problematic compliance liability group
No liability 62 73
Moderate liability 16 19
Marked liability 7 8
Depression liability group
No liability 76 89
Moderate liability 8 10
Marked liability 1 1
HSCT indicates hematopoietic stem cell transplant; aGVHD, acute graft-
versus-host-disease; cGVHD, chronic graft-versus-host disease.
*Variables on which participants in the present study were compared to
nonincluded participants from the larger study.
†A greater proportion of nonincluded participants from the larger study
were classified as having high risk for treatment failure (i.e., high-disease
risk) compared to those in the present study, c2 (1, N5 209)5 4.33, P
5 .04. There were no other differences between the two groups on any
of the other variables examined* at P # .05.
‡High-disease risk: acute myelogenous leukemia (AML) and acute lym-
phoblastic leukemia (ALL) other than first complete remission (CR1),
primary induction failure; acute leukemia from antecedent hematologic
disorder; chronic myelogenous leukemia not in first chronic phase (CML
not CP1); chronic lymphocytic leukemia (CLL); acute bilineage leukemia
(ABlL); non-Hodgkin lymphoma (NHL); Hodgkin disease (HD);
myelodysplastic syndrome (MDS) not refractory anemia (RA) or ringed
sideroblasts (RARS); multiple myeloma (MM); eosinophilic leukemia.
Low-disease risk: ALL CR1; AML CR1; CML CP1; MDS RA, RARS.
§Does not include 1 participant who developed cGVHD from prior
HSCT.
¶Does not include 21 participants who developed aGHVD or 6
participants who died <100 days post-HSCT.
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ity range on the spiritual absence, problematic compli-
ance, and depression subscales were 18% (n 5 15),
27% (n 5 23), 10% (n 5 9), respectively (Table 1).
UnivariateCox regression analyses (Table 2) exam-
ining demographic and biobehavioral covariates on
1-year all-cause mortality indicated that only having
acute leukemia or MDS was significantly associated
with death at 1 year, HR 5 5.00, P 5 .009. Thus, the
presence of acute leukemia or MDS was retained as
a covariate in subsequent multivariate Cox regression
analyses. There were nonsignificant trends for recipi-
ents undergoing (1) myeloablative and (2) unrelated
HSCTs to have greater HRs for 1-year all-cause
mortality; however, these variables were not covaried,
as their 95% confidence intervals (CIs) included a value
of ‘‘1.’’
Tables 3 and 4 present the results of multivariate
Cox regression analyses examining the relationship
between 1-year mortality and spiritual absence and
1-year mortality and problematic compliance, respec-
tively. After covarying for disease type, HSCT recipi-
ents with MBMD spiritual absence scores in the
marked liability range had a greater hazard of 1-year
all-cause mortality (HR 5 2.49, P 5 .043) and 1-year
Table 2. Univariate Cox Regression Analyses for Demographic and Biobehavioral Factors and 1-Year All-Cause Mortality
Variable B HR* 95% CI
Age 0.02 1.01 .98 - 1.05
Sex
Male 1.00
Female 0.06 1.06 .49 - 2.33
Married
Single/never married, divorced, widowed 1.00
Married 0.87 2.38 .71 - 7.99
Race/ethnicity
White, non-Hispanic 1.00
Other (Black/African-American, Asian, or Hispanic of any race) 20.62 .54 .13 - 2.28
Tobacco use at pretransplant
Lifetime nonuser 1.00
Current user (within last 90 days) 20.64 .53 .07 - 4.13
Past user (>90 days abstinence) 0.60 1.82 .81 - 4.10
Alcohol use at pretransplant
Lifetime nonuser 1.00
Current user (within last 90 days) 20.63 .54 .19 - 1.49
Past user (>90 days abstinence) 20.51 .60 .23 - 1.56
Marijuana use at pretransplant
Lifetime nonuser 1.00
Current user (within last 90 days) n/a
Past user (>90 days abstinence) 0.26 1.30 .39 - 4.33
Psychotropic medication/steroid
use at pretransplant
No 1.00
Yes 20.48 .62 .24 - 1.57
Caregiver Identified at
pretransplant
No 0.56 1.74 .24 - 12.91
Yes 1.00
HSCT type
Nonmyeloablative 1.00
Myeloablative 20.73 .48‡ .22 - 1.06
Participant relation to donor
Related 1.00
Unrelated 0.74 2.10‡ .94 - 4.68
Graft source
Bone marrow 1.00
Peripheral blood stem cell 0.41 1.50 .56 - 4.02
Umbilical cord 0.26 1.30 .15 - 11.14
Disease risk†
Low 1.00
High 20.09 .92 .38 - 2.19
Acute leukemia or
myelodysplastic syndrome
No 1.00
Yes 1.61 5.00¶ 1.49 - 16.71
Spiritual absence liability group
No liability 1.00
Moderate liability 212.05 0.00 .00 - n/a
Marked liability 1.00 2.70§ 1.13 - 6.50
Problematic compliance
liability group
No liability 1.00
Moderate liability 0.46 1.59 .62 - 4.10
Marked liability 1.14 3.13§ 1.04 - 9.47
Depression liability group
No liability 1.00
Moderate liability 21.06 .35 .05 - 2.57
Marked liability 211.12 0.00 .00 - n/a
HSCT indicates hematopoietic stem cell transplant. aGVHD, acute graft-versus-host-disease; cGVHD, chronic graft-versus-host disease; CI, confidence
interval; HR, hazard ratio.
*1.00 Denotes reference category.
†High disease risk: acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) other than first complete remission (CR1), primary in-
duction failure; acute leukemia from antecedent hematologic disorder; chronic myelogenous leukemia not in first chronic phase (CML not CP1); chronic
lymphocytic leukemia (CLL); acute bilineage leukemia (ABlL); non-Hodgkin lymphoma (NHL); Hodgkin disease (HD); myelodysplastic syndrome (MDS)
not refractory anemia (RA) or ringed sideroblasts (RARS); multiple myeloma (MM); eosinophilic leukemia. Low disease risk: ALL CR1; AML CR1; CML
CP1; MDS RA, RARS.
‡P < .10
§P < .05
¶P < .01.
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Table 3. Multivariate Cox Regression Analyses Examining
the Relationship Between Spiritual Absence and 1-Year Mor-
tality
b HR* 95% CI
Outcome no. 1: 1-Year mortality,
all-cause
Acute leukemia or
myelodysplastic syndrome
No 1.00
Yes 1.64 5.15§ 1.54 - 17.26
Spiritual absence liability group
No liability 1.00
Moderate liability 212.64 .00 .00 - n/a
Marked liability 0.91 2.49‡ 1.03 - 6.01
Outcome no. 2: 1-Year mortality,
HSCT-related (infection/
sepsis, GVHD)
Acute leukemia or
myelodysplastic syndrome
No 1.00
Yes 1.19 3.28 .72 - 15.07
Spiritual absence liability group
No liability 1.00
Moderate liability 212.93 .00 0.00 - n/a
Marked liability 1.52 4.56§ 1.43 - 14.53
GVHD indicates graft-versus-host disease; CI confidence interval; HR,
hazard ratio.
*1.00 denotes reference category.
†P < .10
‡P < .05
§P < .01.
Table 4. Multivariate Cox Regression Analyses Examining
theRelationship BetweenProblematicCompliance and 1-Year
Mortality
b HR* 95% CI
Outcome no. 1: 1-Year mortality,
all-cause
Acute leukemia or
myelodysplastic syndrome
No 1.00
Yes 1.70 5.46§ 1.62 - 18.39
Problematic compliance
liability group
No lability 1.00
Moderate liability 0.66 1.93 .74 - 5.02
Marked liability 1.25 3.47‡ 1.14 - 10.60
Outcome no. 2: 1-Year mortality,
HSCT-related
(infection/sepsis, GVHD)
Acute leukemia or
myelodysplastic syndrome
No 1.00
Yes 1.27 3.55 .77 - 16.36
Problematic compliance
liability group
No liability 1.00
Moderate liability .23 1.26 .26 - 6.09
Marked Liability 1.73 5.61‡ 1.42 - 22.21
GVHD indicates graft-versus-host disease; HR, hazard ratio; CI, confi-
dence interval.
*1.00 denotes reference category.
†P < .10
‡P < .05
§P < .01.
Figure 1. Unadjusted Kaplan-Meier survival curve for spiritual absence
liability groups. Note: log rank c2 (1, N 5 82) 5 5.37, P 5 .021.
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particular, than those with scores in the no liability
range. Similarly, HSCT recipients with MBMD prob-
lematic compliance scores in themarked liability range
had greater hazard of 1-year all-cause mortality
(HR5 3.47, P5 .029) and 1-year HSCT-related mor-
tality (HR 5 5.61, P 5 .014), in particular, than those
in the no liability range. However, in contrast to
hypotheses, depression liability group was not associ-
ated with 1-year all-cause or HSCT-related mortality
(Ps 5 ns for moderate and marked liability group
HRs). (Spiritual absence, problematic compliance,
and depression liability groups were not associated
with 1-year mortality secondary to disease progression
or new/secondary malignancy.)
Figures 1 and 2 present the unadjusted Kaplan-
Meier survival curves for the spiritual absence and
problematic compliance liability groups, respectively,
using 1-year all-cause mortality as the outcome.
Mean survival time for individuals with marked liabil-
ity in spiritual absence was 680 days (SE 5 172 days,
95% CI 5 343-1017 days), whereas mean survival
for those with no liability in spiritual absence was
1848 days (SE 5 119 days, 95% CI 5 1616-2081
days), log rank c2 (1, N 5 82) 5 5.37, P 5 .021. In
addition, mean survival time for individuals with
marked liability in problematic compliance was 685
days (SE 5 250 days, 95% CI 5 195-1175 days),
whereas mean survival time for those with no liability
in problematic compliance was 1881 days (SE 5 124days, 95% CI 5 1684-2124 days), log rank c2 (1,
N 5 69) 5 4.19, P 5 .041.
To examine whether problematic compliance me-
diated the relationship between spiritual absence and
1-year all-cause mortality, the direct effect of Prob-
lematic Compliance on mortality was assessed after
covarying for the presence of acute leukemia/MDS
and Spiritual Absence. There was no direct effect of
Figure 2. Unadjusted Kaplan-Meier survival curve function for
problematic compliance liability groups. Note: log rank c2 (1, N 5 69)
5 4.19, P 5 .041.
Biol Blood Marrow Transplant 16:1171-1179, 2010 1177Spiritual Absence and Mortality After HSCTproblematic compliance liability group on 1-year
all-cause mortality after covarying for the presence of
acute leukemia/MDS and spiritual absence liability
group (HR 5 2.00, P 5 .32, 95% CI 5 0.52-7.70,
not shown). Thus, problematic compliance was not
supported as a mediator of the relationship between
spiritual absence and mortality. Likewise, spiritual
absence liability group was not associated with 1-year
all-cause mortality after covarying for the presence of
acute leukemia/MDS and the problematic compliance
liability group (HR 5 2.32, P 5 .23, 95% CI 5 0.60-
8.92, not shown).DISCUSSION
The present study suggests that allogeneic HSCT
recipients identified prior to transplant as having
marked liabilities or elevations in spiritual absence
and problematic compliance had greater hazards of
1-year all-cause mortality, in general, and 1-year
HSCT-related mortality due to infection, sepsis, or
GVHD, in particular, following HSCT than those
without liabilities in this areas. Individuals identified
as having marked elevations in depressive symptom-
atology, however, did not have greater hazard of
1-year all-cause or HSCT-related mortality. Further-
more, problematic compliance did not mediate the
relationship between spiritual absence and mortality,
suggesting that both spiritual absence and noncompli-
ance may be individually associated with mortality in
this sample.
Although based on a modest sample size, these
preliminary results add to the growing bodies of liter-
ature demonstrating (1) relationships between psycho-
social factors and survival in HSCT recipients, and (2)
relationships between religiosity/spirituality andhealth outcomes. Furthermore, it is one of the only
published studies, to our knowledge, to suggest a rela-
tionship between religiosity/spirituality and survival in
cancer.
There are several noteworthy limitations of
this study. First, the study’s sample size was modest
(N 5 85), and a small sample size may contribute to
inaccurate inference. However, the study’s sample
size was within the range (N 5 42 [3] to N 5 199 [9])
of other published studies demonstrating similar effect
sizes for the relationship between psychosocial factors
and survival in HSCT. Regardless, only tentative
conclusionsmaybedrawnuntil replicationwitha larger
sample has been performed.
Second, the study’s assessment of spirituality was
limited to only 1 instrument, the MBMD, as this was
the only psychological instrument routinely adminis-
tered to each HSCT candidate during pretransplant
evaluation from 2002 to 2005. This poses several
potential problems. Although the correlation between
the MBMD Spiritual Absence scale and the more
widely used SBI [28] is high, the degree to which
they may be correlated in an HSCT sample is
unknown. Furthermore, because only the MBMD
was used, potentially important mediators of a signifi-
cant spiritual absence-mortality relationship, such as
social support and integration, could not be examined.
Finally, the prevalence of clinically significant depres-
sive symptomatology (10%) in the present sample was
on the lower end of the range reported in other HSCT
samples (9%-17%) [9,30]. This suggests that the
sensitivity of the MBMD’s Depression subscale may
be low in the present sample, which could account
for the lack of relationship between depression and
mortality in the present study.
A third limitation is that although disease type was
controlled for in statistical analyses, all of the known
medical factors that predict survival in this population
could not be covaried. The possibility exists that con-
trolling for one of these medical factors could reduce
or eliminate the statistically significant relationship be-
tween spirituality and survival in this sample. It is also
possible that pre-HSCT biobehavioral factors, such as
prior treatment experiences, may influence spirituality
and compliance scores at the time of HSCT.
Overall, the findings of the present study suggest
that future research should examine these relationships
in larger scale research usingmore comprehensive psy-
chosocial measures. Specifically, this research should
include more comprehensive assessments of spiritual-
ity, depression, and social support quantity and quality.
The SBI-54 [16] may be an appropriate spirituality
assessment instrument, given that it has been validated
in cancer samples. Furthermore, this area of research
may benefit from more comprehensive assessments of
depression using semistructured diagnostic interviews
(eg, Structured Clinical Interview for the Diagnostic
1178 Biol Blood Marrow Transplant 16:1171-1179, 2010D. B. Pereira et al.and Statistical Manual of Mental Disorders—Fourth
Edition [DSM-IV]) [31] and self-report depression
instruments (eg, the Beck Depression Inventory—Sec-
ond Edition [BDI-II]) [32]. In addition, this research
should examine the possible pre-HSCT biopsychoso-
cial factors that may influence spirituality and compli-
ance at the time of transplant.
If a relationship emerges between spirituality and
survival in this larger scale and more comprehensive
research, it may provide support for initiating research
to explore the feasibility and acceptability of delivering
psychospiritual interventions among HSCT recipi-
ents. Although spirituality is a burgeoning area of
research in the field of psycho-oncology [33], little is
still known about how to translate this research into
practical interventions with patients [34]. Broadly
speaking, spirituality based psychological interven-
tions aim to improve mind-body-spirit well-being
via exploration of constructs such as sense of meaning
and purpose, peace, faith, hope, altruism, gratitude,
and forgiveness [34]. These facets of spiritual
well-being may be enhanced through the use of
cognitive-behavioral therapy techniques, creative arts
interventions, life review interviews, and mindfulness/
mantram meditation techniques [19,35-41]. There is
emerging evidence for the feasibility and acceptability
of delivering psychospiritual interventions among
coronary artery bypass graft (CABG) inpatients [42],
a population with similarities to the HSCT inpatients
in terms of treatment intensity, treatment-induced
functional impairment, and length of hospitalization.
If feasibility and acceptability of psychospiritual inter-
ventions are demonstrated inHSCTrecipients, aswell,
research may then examine the effects of psychospiri-
tual interventions on quality of life and clinical out-
comes in this population using a methodologically
rigorous, randomized clinical trial design.ACKNOWLEDGMENTS
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